Laryngo-Rhino-Otologie

LinksSchließen

Referenz

Takahashi H, Tada Y, Saotome T. et al.
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.

J Clin Oncol 2019;
37 (02) 125-134
DOI: 10.1200/JCO.18.00545. (PMID: 30452336)

Bibliographische Angaben herunterladen

Aufrufen in: